Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). The agreement grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite platform and underlying intellectual property. This license is for the discovery, research, development, manufacturing, and commercialization of fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC, with no financial details disclosed.
RenLite Platform and Capabilities
RenLite is part of Biocytogen’s fully human antibody RenMice family. The platform enables the generation of fully human antibody candidates with high specificity, affinity, diversity, and good druggability. These candidates feature a common light chain, which facilitates the assembly of bispecific and multi-specific antibodies with low mismatch and high success rates. The resulting bispecific and multi-specific antibodies maintain a traditional antibody structure and exhibit ideal physiochemical properties, making them advantageous for downstream CMC development.
Significance of the Partnership
This strategic partnership underscores Biocytogen’s commitment to advancing innovative drug discovery platforms and expanding its global reach. By collaborating with Janssen, Biocytogen aims to accelerate the development of novel antibody therapeutics and enhance the therapeutic options available for various diseases.-Fineline Info & Tech
